Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102.47 USD | +1.73% | +6.03% | +9.89% |
09-20 | Centessa Pharmaceuticals Shares Rise After Upgrade From Morgan Stanley | MT |
09-20 | ASML Shares Fall After Downgrade From Morgan Stanley | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Interest and Dividend Income, Total | 18.64B | 11.15B | 10.79B | 21.61B | 50.85B | |||||
Interest Expense, Total | 12.4B | 3.85B | 1.37B | 12.27B | 42.05B | |||||
Net Interest Income | 6.23B | 7.3B | 9.42B | 9.34B | 8.8B | |||||
Brokerage Commission | 3.92B | 4.85B | 5.52B | 4.94B | 4.54B | |||||
Trading and Principal Transactions | 11.1B | 13.99B | 12.81B | 13.93B | 15.26B | |||||
Asset Management Fee | 13.08B | 14.27B | 19.97B | 19.58B | 19.62B | |||||
Underwriting & Investment Banking Fee | 6.16B | 7.67B | 10.99B | 5.6B | 4.95B | |||||
Gain (Loss) on Sale of Investments, Total (Rev) | 47M | 81M | 210M | 70M | 49M | |||||
Other Revenues, Total | 878M | 29M | 832M | 213M | 926M | |||||
Revenues Before Provison For Loan Losses | 41.42B | 48.2B | 59.76B | 53.67B | 54.14B | |||||
Provision For Loan Losses | - | - | 4M | 280M | 532M | |||||
Total Revenues | 41.42B | 48.2B | 59.75B | 53.39B | 53.61B | |||||
Salaries And Other Employee Benefits | 18.66B | 20.7B | 24.53B | 23.01B | 24.2B | |||||
Cost of Services Provided, Total | 8.91B | 9.59B | 11.76B | 12.66B | 13.1B | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Total Operating Expenses | 27.58B | 30.3B | 36.29B | 35.67B | 37.31B | |||||
Operating Income | 13.84B | 17.9B | 23.46B | 17.72B | 16.3B | |||||
Other Non Operating Income (Expenses) | -2.13B | -2.93B | -3.49B | -3.13B | -3.85B | |||||
EBT, Excl. Unusual Items | 11.72B | 14.98B | 19.98B | 14.59B | 12.46B | |||||
Total Merger & Related Restructuring Charges | - | -151M | -102M | -41M | - | |||||
Impairment of Goodwill | - | - | -8M | - | - | |||||
Gain (Loss) on Sale of Assets | - | - | - | - | - | |||||
Asset Writedown | -22M | -70M | -42M | -17M | -43M | |||||
Legal Settlements | -221M | -336M | -157M | -443M | -249M | |||||
Other Unusual Items | -172M | - | - | - | -353M | |||||
EBT, Incl. Unusual Items | 11.3B | 14.42B | 19.67B | 14.09B | 11.81B | |||||
Income Tax Expense | 2.06B | 3.24B | 4.55B | 2.91B | 2.58B | |||||
Earnings From Continuing Operations | 9.24B | 11.18B | 15.12B | 11.18B | 9.23B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 9.24B | 11.18B | 15.12B | 11.18B | 9.23B | |||||
Minority Interest | -195M | -183M | -86M | -150M | -143M | |||||
Net Income - (IS) | 9.04B | 11B | 15.03B | 11.03B | 9.09B | |||||
Preferred Dividend and Other Adjustments | 530M | 496M | 468M | 489M | 557M | |||||
Net Income to Common Incl Extra Items | 8.51B | 10.5B | 14.57B | 10.54B | 8.53B | |||||
Net Income to Common Excl. Extra Items | 8.51B | 10.5B | 14.57B | 10.54B | 8.53B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 5.26 | 6.55 | 8.16 | 6.23 | 5.24 | |||||
Basic EPS - Continuing Operations | 5.26 | 6.55 | 8.16 | 6.23 | 5.24 | |||||
Basic Weighted Average Shares Outstanding | 1.62B | 1.6B | 1.78B | 1.69B | 1.63B | |||||
Net EPS - Diluted | 5.19 | 6.46 | 8.03 | 6.15 | 5.18 | |||||
Diluted EPS - Continuing Operations | 5.19 | 6.46 | 8.03 | 6.15 | 5.18 | |||||
Diluted Weighted Average Shares Outstanding | 1.64B | 1.62B | 1.81B | 1.71B | 1.65B | |||||
Normalized Basic EPS | 4.41 | 5.72 | 6.95 | 5.3 | 4.69 | |||||
Normalized Diluted EPS | 4.35 | 5.65 | 6.84 | 5.24 | 4.64 | |||||
Dividend Per Share | 1.35 | 1.4 | 2.45 | 3.02 | 3.32 | |||||
Payout Ratio | 29.05 | 24.91 | 27.74 | 48.97 | 63.42 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
Effective Tax Rate - (Ratio) | 18.26 | 22.46 | 23.12 | 20.65 | 21.87 | |||||
Current Domestic Taxes | 1.13B | 2.04B | 3.03B | 2.96B | 1.73B | |||||
Current Foreign Taxes | 766M | 1.45B | 1.52B | 799M | 1.31B | |||||
Total Current Taxes | 1.9B | 3.49B | 4.54B | 3.76B | 3.05B | |||||
Deferred Domestic Taxes | 231M | -287M | 22M | -945M | -354M | |||||
Deferred Foreign Taxes | -66M | 37M | -18M | 96M | -109M | |||||
Total Deferred Taxes | 165M | -250M | 4M | -849M | -463M | |||||
Normalized Net Income | 7.13B | 9.18B | 12.4B | 8.97B | 7.64B | |||||
Non-Cash Pension Expense | 39M | 71M | 91M | 81M | 35M | |||||
Supplemental Operating Expense Items | ||||||||||
Stock-Based Comp., G&A Exp. (Total) | - | - | 2.08B | 1.88B | 1.71B | |||||
Stock-Based Comp., Other (Total) | 1.15B | 1.31B | - | - | - | |||||
Total Stock-Based Compensation | 1.15B | 1.31B | 2.08B | 1.88B | 1.71B |